bioMerieux SA (BIM):医療機器:M&Aディール及び事業提携情報

GlobalDataが発行した調査報告書(DATA904C7387)
◆英語タイトル:bioMerieux SA (BIM) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA904C7387
◆発行会社(リサーチ会社):GlobalData
◆発行日:2018年10月
◆ページ数:82
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:フランス
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
bioMerieux SA (bioMerieux), a subsidiary of Institut Merieux SA, develops, manufactures and markets in vitro diagnostic solutions for private and hospital laboratories. The company offers diagnostic solutions such as systems, reagents and software. Its products are used to diagnose infectious diseases, cardiovascular diseases and targeted cancers. The company also provides solutions for the enumeration of microbial flora, to detect specific pathogenic bacteria, and to monitor air and surface quality and sterility testing for agri-food, cosmetics and pharmaceutical industries. The company distributes its products directly and also through a network of distributors across the world. bioMerieux is headquartered in Marcy l’Etoile, France.

bioMerieux SA (BIM) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
bioMerieux SA, Medical Equipment, Deals By Year, 2012 to YTD 2018 7
bioMerieux SA, Medical Equipment Deals By Type, 2012 to YTD 2018 8
bioMerieux SA, Medical Equipment, Deals By Region, 2012 to YTD 2018 9
bioMerieux SA, Medical Equipment, Deals By Market, 2012 to YTD 2018 10
bioMerieux SA, Medical Equipment, Deals Summary, 2012 to YTD 2018 11
bioMerieux SA, Medical Equipment, Deal Details 13
Venture Financing 13
Qvella Raises USD20 Million in Series B Financing 13
Astute Medical Raises Additional USD1 Million in Venture Financing 15
Astute Medical Raises USD2 Million in Venture Financing 16
Astute Medical Raises USD20 Million in Venture Financing 17
Astute Medical Secures USD40 Million in Venture Funding from CRG (Capital Royalty) 18
Astute Medical Raises USD20 Million in Venture Financing 19
Quanterix Raises US$19 Million In Series C Financing 20
BioFire Diagnostics Raises USD25 Million in Financing Round 22
Astute Medical Raises US$40.4 Million In Series C Financing 23
Astute Medical Raises US$2 Million In Venture Financing 25
Private Equity 26
BioTheranostics Raises USD32 Million in Private Equity Financing 26
Athyrium Opportunities Fund Invests US$20 Million In BioFire Diagnostics 27
Partnerships 28
Quanterix Enters into Licensing Agreement with bioMerieux 28
BioMerieux Enters into Licensing Agreement with Astute Medical 29
Seegene Enters Into Licensing Agreement With BioMerieux For DPO And TOCE Technologies 30
Lonza Walkersville Enters Into Licensing Agreement With Hyglos For Endotoxin Detection Patents 31
bioMerieux Enters Into Licensing Agreement With Quanterix For Simoa Technology 32
Astute Medical Enters into Distribution Agreement with bioMerieux 33
Biomerieux Enters into Agreement with Banyan Biomarkers 34
ITL Biomedical Enters into Distribution Agreement with bioMerieux Canada 35
Biotheranostics Enters into Agreement with Syapse 36
BioMerieux Enters into Co-Development Agreement with Copan Italia 37
BioMerieux Enters into Distribution Agreement with Copan 38
Astute Medical Enters into Distribution Agreement with Fosun Long March 39
BioMerieux Enters into Distribution Agreement with Copan for WASP and WASPLab 40
BioMerieux Enters into Co-Development Agreement with Illumina 41
Astute Medical Expands its Co-Marketing Agreement with Ortho-Clinical Diagnostics 42
PathoGenetix And Applied Maths Enter Into Technology Integration Agreement For Pathogen Strain Typing 43
OpGen Enters Into Agreement With Applied Maths To Develop Whole Genome Mapping Software 44
Thermo Fisher Scientific Extends Co-Development Agreement With bioMerieux For Procalcitonin Testing 45
Equity Offering 46
Astute Medical Raises USD43 Million in Private Palcement of Shares 46
Debt Offering 47
bioMerieux Completes Private Placement Of Bonds Due 2020 For US$406.6 Million 47
Acquisition 48
bioMerieux Acquires Astute Medical for USD90 Million 48
bioMerieux to Acquire 34% Stake in Sysmex bioMerieux from Sysmex 49
BioMerieux Acquires Applied Maths 50
BioMerieux Completes Acquisition Of BioFire Diagnostics For US$486 Million 51
bioMerieux SA – Key Competitors 53
bioMerieux SA – Key Employees 54
bioMerieux SA – Locations And Subsidiaries 56
Head Office 56
Other Locations & Subsidiaries 56
Recent Developments 60
Financial Announcements 60
Apr 19, 2018: biomerieux – First-quarter 2018 Business Review 60
Jan 23, 2018: bioMerieux – Fourth-Quarter 2017 Business Review 62
Aug 30, 2017: bioMerieux – First-Half 2017 Results 65
Jul 20, 2017: bioMerieux – Second-Quarter 2017 Business Review 68
Apr 20, 2017: bioMerieux – First-Quarter 2017 Business Review 70
Mar 01, 2017: bioMerieux – 2016 Financial Results 73
Jan 19, 2017: bioMerieux – Fourth-Quarter 2016 Business Review 76
Corporate Communications 78
Apr 23, 2018: bioMerieux and the University of Antwerp award scholarships to three healthcare professionals for their commitment to improve antibiotic use in order to combat antimicrobial resistance 78
Product News 79
Jan 05, 2017: Quanterix to Present at The 35th Annual J.P. Morgan Healthcare Conference 79
Other Significant Developments 80
Oct 18, 2017: bioMerieux – Business review for the nine months ended September 30, 2017 80
Appendix 82
Methodology 82
About GlobalData 82
Contact Us 82
Disclaimer 82

List of Tables
bioMerieux SA, Medical Equipment, Key Facts, 2017 2
bioMerieux SA, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
bioMerieux SA, Medical Equipment, Deals By Year, 2012 to YTD 2018 7
bioMerieux SA, Medical Equipment Deals By Type, 2012 to YTD 2018 8
bioMerieux SA, Medical Equipment, Deals By Region, 2012 to YTD 2018 9
bioMerieux SA, Deals By Market, 2012 to YTD 2018 10
bioMerieux SA, Medical Equipment, Deals Summary, 2012 to YTD 2018 11
Qvella Raises USD20 Million in Series B Financing 13
Astute Medical Raises Additional USD1 Million in Venture Financing 15
Astute Medical Raises USD2 Million in Venture Financing 16
Astute Medical Raises USD20 Million in Venture Financing 17
Astute Medical Secures USD40 Million in Venture Funding from CRG (Capital Royalty) 18
Astute Medical Raises USD20 Million in Venture Financing 19
Quanterix Raises US$19 Million In Series C Financing 20
BioFire Diagnostics Raises USD25 Million in Financing Round 22
Astute Medical Raises US$40.4 Million In Series C Financing 23
Astute Medical Raises US$2 Million In Venture Financing 25
BioTheranostics Raises USD32 Million in Private Equity Financing 26
Athyrium Opportunities Fund Invests US$20 Million In BioFire Diagnostics 27
Quanterix Enters into Licensing Agreement with bioMerieux 28
BioMerieux Enters into Licensing Agreement with Astute Medical 29
Seegene Enters Into Licensing Agreement With BioMerieux For DPO And TOCE Technologies 30
Lonza Walkersville Enters Into Licensing Agreement With Hyglos For Endotoxin Detection Patents 31
bioMerieux Enters Into Licensing Agreement With Quanterix For Simoa Technology 32
Astute Medical Enters into Distribution Agreement with bioMerieux 33
Biomerieux Enters into Agreement with Banyan Biomarkers 34
ITL Biomedical Enters into Distribution Agreement with bioMerieux Canada 35
Biotheranostics Enters into Agreement with Syapse 36
BioMerieux Enters into Co-Development Agreement with Copan Italia 37
BioMerieux Enters into Distribution Agreement with Copan 38
Astute Medical Enters into Distribution Agreement with Fosun Long March 39
BioMerieux Enters into Distribution Agreement with Copan for WASP and WASPLab 40
BioMerieux Enters into Co-Development Agreement with Illumina 41
Astute Medical Expands its Co-Marketing Agreement with Ortho-Clinical Diagnostics 42
PathoGenetix And Applied Maths Enter Into Technology Integration Agreement For Pathogen Strain Typing 43
OpGen Enters Into Agreement With Applied Maths To Develop Whole Genome Mapping Software 44
Thermo Fisher Scientific Extends Co-Development Agreement With bioMerieux For Procalcitonin Testing 45
Astute Medical Raises USD43 Million in Private Palcement of Shares 46
bioMerieux Completes Private Placement Of Bonds Due 2020 For US$406.6 Million 47
bioMerieux Acquires Astute Medical for USD90 Million 48
bioMerieux to Acquire 34% Stake in Sysmex bioMerieux from Sysmex 49
BioMerieux Acquires Applied Maths 50
BioMerieux Completes Acquisition Of BioFire Diagnostics For US$486 Million 51
bioMerieux SA, Key Competitors 53
bioMerieux SA, Key Employees 54
bioMerieux SA, Subsidiaries 56

List of Figures
bioMerieux SA, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
bioMerieux SA, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
bioMerieux SA, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
bioMerieux SA, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
bioMerieux SA, Medical Equipment, Deals By Year, 2012 to YTD 2018 7
bioMerieux SA, Medical Equipment, Deals by Type, 2012 to YTD 2018 8
bioMerieux SA, Medical Equipment, Deals By Region, 2012 to YTD 2018 9
bioMerieux SA, Medical Equipment, Deals by Market, 2012 to YTD 2018 10

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ bioMerieux SA (BIM):医療機器:M&Aディール及び事業提携情報(bioMerieux SA (BIM) - Medical Equipment - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆